BRAF and neoplasm: For evaluation of the viability and accuracy of a novel RNA-based blood assay to discriminate individuals with a high-risk tumor mutation in patients with PTC, circulating BRAFV600Elevels were compared with surgical pathologic DNA-based tissue BRAF mutation assays 165.